Compare CGNT & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGNT | OABI |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.0M | 239.0M |
| IPO Year | N/A | N/A |
| Metric | CGNT | OABI |
|---|---|---|
| Price | $9.88 | $2.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $14.00 | $6.67 |
| AVG Volume (30 Days) | 283.0K | ★ 571.9K |
| Earning Date | 12-09-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $388,304,000.00 | $21,094,000.00 |
| Revenue This Year | $15.30 | N/A |
| Revenue Next Year | $11.30 | $66.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.27 | 3.36 |
| 52 Week Low | $7.64 | $1.22 |
| 52 Week High | $11.66 | $4.08 |
| Indicator | CGNT | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 76.43 | 73.35 |
| Support Level | $8.15 | $1.90 |
| Resistance Level | $9.97 | $2.04 |
| Average True Range (ATR) | 0.31 | 0.11 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 95.41 | 88.68 |
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.